Search

Your search keyword '"Wechalekar, Ashutosh"' showing total 786 results

Search Constraints

Start Over You searched for: Author "Wechalekar, Ashutosh" Remove constraint Author: "Wechalekar, Ashutosh" Language english Remove constraint Language: english
786 results on '"Wechalekar, Ashutosh"'

Search Results

2. Abstract 4144740: Characteristics and Natural History of Early ATTR Cardiac Amyloid Infiltration

3. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort

4. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748

6. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

7. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

8. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

9. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA

10. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

11. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

13. Abstract 11740: Redefining Cardiac Involvement in Systemic Immunoglobulin Light Chain Amyloidosis and Treatment Implications

15. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

20. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

22. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

23. Search for AL amyloidosis risk factors using Mendelian randomization

24. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

25. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

28. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis.

29. Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab.

30. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime.

33. Standardized reporting of monoclonal immunoglobulin–associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group

34. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

35. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis

36. Refining prognostication in systemic AL amyloidosis: limited value of dFLC.

38. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance

40. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles

41. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

42. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

43. Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.

44. Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.

46. Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.

49. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome

Catalog

Books, media, physical & digital resources